Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables

被引：198
作者：
Anderson, James R. [1 ]
Cain, Kevin C. [2 ]
Gelber, Richard D. [3 ,4 ]
机构：
[1] Univ Nebraska, Coll Publ Hlth, Omaha, NE 68182 USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 24期
关键词：
D O I：
10.1200/JCO.2008.16.1000
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3913 / 3915
页数：3
相关论文
共 20 条
  • [11] Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival
    Moreton, P
    Kennedy, B
    Lucas, G
    Leach, M
    Rassam, SMB
    Haynes, A
    Tighe, L
    Oscier, D
    Fegan, C
    Rawstron, A
    Hillmen, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) : 2971 - 2979
  • [12] ASSESSING THE EFFECT OF TOXICITY ON PROGNOSIS - METHODS OF ANALYSIS AND INTERPRETATION
    PROPERT, KJ
    ANDERSON, JR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (05) : 868 - 870
  • [13] Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Romond, EH
    Perez, EA
    Bryant, J
    Suman, VJ
    Geyer, CE
    Davidson, NE
    Tan-Chiu, E
    Martino, S
    Paik, S
    Kaufman, PA
    Swain, SM
    Pisansky, TM
    Fehrenbacher, L
    Kutteh, LA
    Vogel, VG
    Visscher, DW
    Yothers, G
    Jenkins, RB
    Brown, AM
    Dakhil, SR
    Mamounas, EP
    Lingle, WL
    Klein, PM
    Ingle, JN
    Wolmark, N
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) : 1673 - 1684
  • [14] Shuster JJ, 1998, J CLIN ONCOL, V16, P393
  • [15] A NON-PARAMETRIC GRAPHICAL REPRESENTATION OF THE RELATIONSHIP BETWEEN SURVIVAL AND THE OCCURRENCE OF AN EVENT - APPLICATION TO RESPONDER VERSUS NON-RESPONDER BIAS
    SIMON, R
    MAKUCH, RW
    [J]. STATISTICS IN MEDICINE, 1984, 3 (01) : 35 - 44
  • [16] SIMON R, 1985, CANCER TREAT REP, V69, P1
  • [17] 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
    Smith, Ian
    Procter, Marion
    D Gelber, Richard
    Guillaume, Sebastien
    Feyereislova, Andrea
    Dowsett, Mitch
    Goldhirsch, Aron
    Untch, Michael
    Mariani, Gabriella
    Baselga, Jose
    Kaufmann, Manfred
    Cameron, David
    Bell, Richard
    Bergh, Jonas
    Coleman, Robert
    Wardley, Andrew
    Harbeck, Nadia
    Lopez, Roberto I.
    Mallmann, Peter
    Gelmon, Karen
    Wilcken, Nicholas
    Wist, Erik
    Sanchez Rovira, Pedro
    Piccart-Gebhart, Martine
    [J]. LANCET, 2007, 369 (9555) : 29 - 36
  • [18] CHEMOTHERAPY FOR ADENOCARCINOMA OF THE LUNG (WHO III) - A RANDOMIZED STUDY OF VINDESINE VERSUS LOMUSTINE, CYCLOPHOSPHAMIDE, AND METHOTREXATE VERSUS ALL 4 DRUGS
    SORENSEN, JB
    HANSEN, HH
    DOMBERNOWSKY, P
    BORK, E
    MALMBERG, R
    AABO, K
    BODKER, B
    HANSEN, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (08) : 1169 - 1177
  • [19] UNTCH M, ANN ONCOL
  • [20] COMPARING SURVIVAL OF RESPONDERS AND NONRESPONDERS AFTER TREATMENT - A POTENTIAL SOURCE OF CONFUSION IN INTERPRETING CANCER CLINICAL-TRIALS
    WEISS, GB
    BUNCE, H
    HOKANSON, JA
    [J]. CONTROLLED CLINICAL TRIALS, 1983, 4 (01): : 43 - 52
12